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Abstract
Objective—To evaluate the peer-reviewed literature on iodine deficiency and hypothyroxinemia
in pregnancy.
Methods—We review published studies on isolated hypothyroxinemia in pregnancy,
methodology of free thyroxine (T4) assays, impact of iodine deficiency on free T4 levels, and
status of ongoing prospective randomized trials of isolated hypothyroxinemia during pregnancy.
Results—Hypothyroxinemia during pregnancy is common. Studies have demonstrated the
pivotal role exerted by maternal T4 on fetal brain development and the negative impact of
hypothyroxinemia on neurobehavioral performance in offspring. Two intervention studies have
demonstrated a positive effect on neurodevelopment in children of mothers promptly
supplemented with iodine compared with the neurodevelopment in children of nonsupplemented
mothers. Free T4 assays presently in clinical use have limitations. Preliminary results of the
Controlled Antenatal Thyroid Study (CATS) are somewhat mixed, and the National Institutes of
Health Maternal Fetal Medicine Thyrotropin Study (TSH Study) will be completed in 2015.
Knowledge regarding the impact of isolated hypothyroxinemia has progressed, but major
questions remain. An optimal diagnostic test for free T4 during pregnancy (accurate, inexpensive,
and widely available) remains elusive. Trimester-specific normative data and normal ranges from
different geographic regions do not exist.
Conclusions—Data published to date are insufficient to recommend levothyroxine therapy in
pregnant women with isolated hypothyroxinemia. Adequate iodine intake should be recommended
before conception and early in pregnancy.
INTRODUCTION
The condition of isolated hypothyroxinemia in pregnancy is defined as the presence of a free
thyroxine (FT4) value below the 2.5th percentile with a thyrotropin (TSH) level within the
reference range. The critical questions are whether hypothyroxinemia in pregnancy is
associated with negative maternal and fetal outcomes and whether treatment with
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levothyroxine can prevent the adverse effects. These questions remain unanswered for the
following reasons: first, the definition of what constitutes a FT4 level below the 2.5th
percentile is unclear because regional and iodine status reference ranges have not been
established; second, and perhaps equally problematic, is that the accuracy of commonly used
FT4 measurements during pregnancy is questionable; and third, research to date evaluating
the effect of isolated hypothyroxinemia on maternal and fetal outcomes has yielded
conflicting data.
The present review aims to examine the controversial condition of isolated
hypothyroxinemia, from laboratory evaluation to studies of intervention. Clarification of the
impact of isolated hypothyroxinemia is critical to the care of pregnant women, and recently
completed clinical trials, as well as a National Institutes of Health Maternal Fetal Medicine
multicenter trial (called the TSH trial) projected to be presented in 2015, will hopefully
provide much needed clarity.
THE PROBLEM OF IODINE DEFICIENCY
Iodine deficiency and thyroid autoimmunity affect TSH and FT4 concentrations. During
pregnancy, a complex combination of factors specific to the pregnant state results in
profound alterations in the thyroidal economy. Moreover, in iodine-deficient pregnant
women, increased thyroidal stimulation induces, in turn, a sequence of events leading from
physiological adaptation of the thyroidal economy observed in healthy iodine-sufficient
pregnant women to pathologic alterations affecting both thyroid function and the anatomic
integrity of the thyroid gland. Even in mild iodine deficiency, signs of thyroid adaptation are
represented by increased thyroid volume, increased thyroglobulin production, and elevated
TSH and decreased FT4 values (1-4). The National Health and Nutrition Examination
Survey 2003-2004 demonstrated that the US population was generally iodine sufficient as
measured by urinary iodine concentration (160 μg/L), but showed that 11.3% of the
population had a low urinary iodine concentration (<50 μg/L). Moreover, among all women
of reproductive age (pregnant and nonpregnant), the median urinary iodine concentration
was 139 μg/L, and 15.1% of women had a urinary iodine concentration less than 50 μg/L
(5). The situation is certainly worse in Europe, especially in those countries where iodine
supplementation is not mandatory. In those regions, pregnant women rarely maintain iodine
intake at the levels recommended for pregnant women by the World Health Organization
(250 mcg daily) (6).
The spectrum of iodine deficiency varies widely across Europe. An observational study of
iodine sufficiency in pregnancy was conducted in Toulouse (southwestern France), a region
thought to be iodine replete because of its relative proximity to the sea and the fish-eating
habits of the population. Nevertheless, 75% of participants in a cohort of pregnant women
from this region had urinary iodine excretion below 100 μg/L (7). As a component of a
large, prospective, randomized trial of levothyroxine therapy in women with subclinical
hypothyroidism and hypothyroxinemia (Controlled Antenatal Thyroid Study [CATS]), the
iodine status of 261 hypothyroid/hypothyroxinemic women and 526 euthyroid women from
Turin, Italy, and 374 hypothyroid/hypothyroxinemic women and 480 euthyroid women from
Cardiff, Wales, were evaluated. The women were selected from the larger cohort on the
basis of availability of stored urine samples and thyroid function data. Analysis of urine
samples revealed the median urinary iodine to be low in Cardiff (98 μg/L) and extremely
low in Turin (52 μg/L) (8). In 1998, a different scenario was documented in Sweden, where
the mean 24-hour urinary iodine concentration was 140 μg/L in the first trimester of
pregnancy—a level that still suggests lessthan-adequate iodine daily intake (9).
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Sufficient iodine intake during pregnancy is sometimes adversely affected by a public health
effort to limit the overall salt intake of the population, so as to decrease the incidence of
hypertension, heart disease, and stroke. In a study performed in Columbia, a country that
uses iodized salt to correct iodine deficiency, 50% of women had restricted salt intake
during pregnancy, resulting in a significant TSH elevation at the time of delivery (10). These
findings emphasize the concept that in areas where iodized salt is used to prevent iodine
deficiency, dietary salt restriction, as often happens during gestation, may further increase
the risk of becoming hypothyroxinemic.
DIAGNOSING HYPOTHYROXINEMIA
Evidence suggests that maternal hypothyroxinemia alone poses an increased risk for fetal
neurodevelopmental deficits. This is of particular potential importance since normal serum
concentrations of maternal triiodothyronine (T3) could conceivably prevent a TSH elevation,
but do not compensate for low thyroxine (T4) concentrations and the resulting neurologic
damage. Therefore, TSH assessment alone is insufficient in detecting hypothyroxinemia.
Hypothyroxinemia is prevalent both in areas replete with iodine and regions of iodine
insufficiency. Although thyroid autoimmunity carries a 5-fold increased risk of
hypothyroidism, in geographic areas that are iodine deficient, iodine insufficiency seems to
be a main determinant in the occurrence of thyroid underfunction (11). Prolonged iodized
salt significantly improves maternal thyroid economy and reduces the risk of maternal
thyroid insufficiency during gestation, probably because of the near-complete restoration of
intrathyroidal iodine stores (12).
FT4 immunoassays currently available on the market are essentially FT4 estimate tests that
do not measure FT4 directly and are known to be sensitive to alterations in binding proteins
(13). They perform reasonably well in nonpregnant conditions by reporting low FT4 levels
in thyroid hormone deficiency and high FT4 levels in thyroid hormone excess (14). As a
result, pregnancy-induced elevation in T4-binding globulin and nonesterified fatty acids, as
well as lower concentrations of albumin relative to serum samples of nonpregnant women,
can influence FT4 measurement (14-17). A comparison of methods demonstrated that
albumin-dependent immunoassays had marked negative bias with up to 50% of subnormal
values, while other methods gave values above their nonpregnant reference values (18).
FT4 IMMUNOASSAYS
The uncertainty around FT4 estimates in pregnancy has called into question the wisdom of
relying on FT4 immunoassays during pregnancy (15). The difficulty in measurement of FT4
is further complicated by the fact that only 0.03% of total serum T4 is unbound. It is
therefore challenging to measure FT4 (measured in picomoles) in the presence of high
concentrations of bound T4 (measured in nanomoles), especially during pregnancy when
serum binding-protein concentrations are markedly elevated and in the presence of
heterophilic antibodies (19-21). Moreover, immunoassays are prone to error by disruption of
the original equilibrium, and depend on dilution, temperature, buffer composition, affinity
and concentration of the T4 antibody reagent, and T4-binding capacity of the serum sample
(22). These conditions make the conventional immunoassay methods unreliable with often
nonreproducible results among different kits (18). Because FT4 measurement by liquid
chromatography/tandem mass spectrometry (LC/MS/MS) is not readily available in most
clinical laboratories, clinicians should use whichever measure for or estimate of FT4 that is
available in their laboratory, being aware of the limitations of each method.
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TRIMESTER-SPECIFIC REFERENCE RANGES
FT4 reference ranges in pregnancy vary widely among methods; therefore, interpretation of
FT4 values requires method-specific ranges (16,17). Such ranges are also influenced by the
iodine status of the population studied. It is customary for laboratories to adopt the reference
ranges provided by the manufacturer of the test. Typically, the characteristics of these
reference cohorts are not disclosed and may differ in iodine intake and ethnicity to an extent
that compromises the value of adopting the manufacturer ranges across different
populations. Furthermore, FT4 reference ranges provided by the manufacturers have been
established using pools of serum samples from healthy, nonpregnant persons and such
reference ranges are not valid in the pregnant state. Therefore, it has been proposed to adapt
serum FT4 reference ranges that are laboratory-specific and trimester-specific for use during
pregnancy, but, so far, no worldwide consensus has been reached on such “pregnancy-
adapted” ranges (Fig. 1). Therefore, caution is recommended in the interpretation of serum
FT4 levels in pregnancy.
LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY
More recently, free thyroid hormones have been measured in the dialysate or ultrafiltrate
after serum online solid phase extraction by LC/MS/MS. The method is regarded as a major
advancement, with higher specificity than immunoassays and great potential to be applied in
the routine assessment of FT4 and free triiodothyronine (FT3). It should be noted that before
FT4 hormone measurement, the free and bound T4 must be physically separated.
Equilibrium dialysis and ultrafiltration are 2 methods used for physical separation of serum
free T4 before analysis of the dialysate or ultrafiltrate. These separation techniques are labor-
intensive, time-consuming, and costly. Compared with FT4 measured by immunoassays,
free thyroid hormone concentrations measured by LC/MS/MS correlate well with inverse
log TSH values (24). However, this correlation decreases during pregnancy (r = 0.11 for FT4
LC/MS/MS, and r = −0.06 for FT4 immunoassay), suggesting changes in the set point of the
hypothalamuspituitary-thyroid axis during pregnancy. A working group of the International
Federation of Clinical Chemistry and Laboratory Medicine recommends the use of isotope
dilution LC/MS/MS as the criterion standard procedure for the measurement of serum FT4
(25). Tandem mass spectrometry is ideally suited for generating reliable and reproducible
trimester-specific reference intervals for FT4 (26). Using direct equilibrium dialysis and LC/
MS/MS, the 95% FT4 reference intervals during pregnancy decreased gradually with
advancing gestational age: from 1.08-1.82 ng/dL in week 14 to 0.86-1.53 ng/dL in week 20
(27). In comparison, using ultrafiltration followed by isotope dilution LC/MS/MS, serum
FT4 concentrations (mean ± standard error) were 1.13 ± 0.23 ng/dL in the first trimester,
0.92 ± 0.30 ng/dL in the second trimester, 0.86 ± 0.21 ng/dL in the third trimester, and 0.93
± 0.25 ng/dL in nonpregnant women (25). Using a direct analogue immunoassay on the
same serum samples, FT4 values were 1.05 ± 0.22 ng/dL, 0.88 ± 0.17 ng/dL, and 0.89 ± 0.17
ng/dL in the first, second, and third trimester, respectively. Serum FT4 by LC/MS/MS
correlated very well with serum FT4 measured by classic equilibrium dialysis, but
correlation with results from the FT4 immunoassay were less satisfactory (25).
COMPLICATIONS ASSOCIATED WITH MATERNAL HYPOTHYROXINEMIA
Despite the limitations of FT4 assays, multiple studies have demonstrated that low-normal
FT4 concentrations are associated with adverse outcomes in the offspring. Perhaps the best-
known study was published in the New England Journal of Medicine by Haddow and
colleagues in 1999 (28). The Haddow et al study revealed that maternal hypothyroidism
present in the second trimester of gestation, which was not adequately treated with thyroid
hormone, was associated with a lower intelligence quotient (IQ) in the offspring. In that
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retrospective study, the authors selected 62 pregnant women with serum TSH values above
the 98th percentile of the values for all pregnant women tested (n = 25 216), in combination
with low FT4 values. Their children underwent IQ tests (Wechsler Intelligence Scale for
Children, third edition) at ages 7 to 9 years, which revealed a mean IQ that was 4 points
lower than the IQ of control children (P = .06). Furthermore, 15% of the children of the
identified mothers had IQ scores of 85 or less, compared with 5% of the matched control
children with euthyroid mothers. Of the 62 women with thyroid deficiency, 48 were not
treated with levothyroxine during pregnancy. The full-scale IQ scores of these 48 children
averaged 7 points lower than that of the control children (P = .005), with 19% of these
children having IQ scores of 85 or less.
In the same year, Pop et al evaluated the relationship between FT4 values of women during
gestation and psychomotor development of their infants (29). Children of women with FT4
levels below the 5th and 10th percentiles at 12 weeks’ gestation had significantly lower
scores on the Bayley Psychomotor Developmental Index (PDI) scale at 10 months of age
than children of mothers with higher FT4 values. A positive correlation was found between
the mothers’ FT4 concentrations at 12 weeks’ gestation and children’s PDI scores. The study
also demonstrated that low FT4 levels occurring in late pregnancy (32 weeks’ gestation) did
not affect the children’s neurodevelopment, and that if maternal FT4 normalized by 24 and
32 weeks’ gestation, the negative effect on the PDI disappeared. A few years later, the same
group of investigators evaluated the mental and motor development in 1- and 2-year-old
children of mothers who experienced hypothyroxinemia (FT4 below the 10th percentile) at
12 weeks’ gestation (30). These children had PDI scores that were significantly lower (by 8
to 10 points) than scores of children born to euthyroxinemic mothers (FT4 values between
50th and 90th percentiles).
Such results have been confirmed by Vermiglio et al (31). These authors compared the
neuropsychological development of children whose mothers came from a moderately
iodine-deficient area and children of mothers from a marginally iodine-sufficient area.
Results showed that the mothers from the iodine-deficient area experienced lower FT4
values during gestation than mothers from the iodine-sufficient area. Furthermore, the
offspring of hypothyroxinemic mothers had an increased incidence of attention deficit and
hyperactivity disorder, as well as a reduced IQ, compared with controls.
In 2006, Kooistra et al demonstrated that newborns of hypothyroxinemic mothers (FT4
below the 10th percentile at 12 weeks’ gestation) who were evaluated 3 weeks after delivery
with the Neonatal Behavioural Assessment Scale had significantly lower scores in the
orientation index than control children (children from mothers with total T4 values between
the 50th and 90th percentiles) (32). A recent study from China showed that children of
women with thyroid abnormalities at 16 to 20 weeks’ gestation (subclinical hypothyroidism,
hypothyroxinemia, and elevated thyroperoxiase antibody titers) had mean intelligence and
motor scores significantly lower than those of control children. Increased maternal serum
TSH, decreased maternal serum total T4, and elevated maternal thyroperoxidase antibody
titers were separately associated either with lower intelligence scores or poorer motor scores
in the offspring (33).
Most recently, Henrichs et al studied associations of maternal hypothyroxinemia with
cognitive functioning in early childhood. The authors conducted a population-based cohort
study in the Netherlands involving 3659 children and their mothers. The mothers were
defined as having mild or severe hypothyroxinemia on the basis of serum FT4
concentrations below the 10th and 5th percentile, respectively. Results showed that maternal
TSH was not related to cognitive outcomes, while an increase in maternal FT4 predicted a
lower risk of expressive language delay at 30 months of age. Furthermore, both mild and
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severe maternal hypothyroxinemia were associated with a higher risk of expressive language
delay at 18 and 30 months. Severe maternal hypothyroxinemia also predicted a higher risk
of nonverbal cognitive delay. On the basis of such results, the authors concluded that
maternal hypothyroxinemia represents a risk factor for cognitive delay in early childhood
(34). Long-term follow-up would be useful in identifying whether the neurodevelopment
delay found in offspring of mothers with severe maternal hypothyroxinemia persists
throughout childhood.
IN VITRO AND EXPERIMENTAL EVIDENCE FOR A ROLE OF MATERNAL T4
IN PREGNANCY
A lack of thyroid hormone during early fetal life results in irreversible brain damage The
detrimental effect of iodine deficiency and maternal hypothyroxinemia on fetal brain
development are probably related to reduced maternal T4 transfer to the fetus before the
onset of fetal thyroid function (35,36). During the first trimester, the fetus is completely
dependent on maternal T4, and although T4 in the fetal compartment is about 100 times
lower than in the maternal serum, the FT4 concentrations are about one-third the maternal
concentration (35,36). The development of the fetal brain is dependent on T4, as all T3 in the
fetal brain is locally derived from T4 by the action of the D2 deiodinase. Maternal T3 is not
used by the fetal brain (37-39). Study of the human fetal brain from 13 to 20 weeks’
gestation has revealed specific developmental patterns for thyroid hormone and D2 and D3
deiodinases, with spatial and temporal specificity and different patterns for the cerebral
cortex and the cerebellum. Low maternal T4 prevents the normal T3 increases in each of the
developing brain areas (40).
In rats, a mild and transient deficiency of maternal thyroid hormones for only 3 days, at the
onset of corticogenesis, irreversibly deranges the migration of radial neurons and the
cytoarchitecture of the cortex and hippocampus unless levothyroxine is administered within
a short time span (41). Moreover, a condition of iodine deficiency is able to cause
irreversible damage to the developing fetal brain, as thyroid hormones have a pivotal role in
several neurobiological processes, such as neurogenesis, neuronal migration, axon and
dendrite formation, myelination, synaptogenesis, and neurotransmission (42,43). In essence,
strong and consistent evidence confirms that maternal hypothyroidism and
hypothyroxinemia negatively affects newborn development (44). Furthermore, although
early maternal hypothyroxinemia can be important in fetal brain development, iodine
deficiency may be even worse than isolated maternal hypothyroxinemia/hypothyroidism
because of the additional problem of fetal hypothyroidism due to the lack of iodine
availability for fetal thyroid hormone synthesis (45).
STUDIES OF INTERVENTION
Two studies conducted in Spain have demonstrated the deleterious effects of iodine
deficiency and the positive role exerted by adequate iodine supplementation initiated early
in pregnancy. Berbel et al showed that a delay of 6 to 10 weeks in iodine supplementation
(200 mcg daily of potassium iodide) in hypothyroxinemic mothers at the beginning of
gestation increased the risk of neurodevelopmental delay in the progeny (46). In particular,
children from hypothyroxinemic mothers had lower scores in gross and fine motor
coordination and socialization performances, while no significant differences were found on
language quotients. Velasco et al compared the psychological development of infants aged 3
to 18 months whose mothers had received potassium iodide, 300 mcg daily, during the first
trimester of pregnancy (133 cases) with the psychological development of infants whose
mothers had not received iodine supplementation (61 controls). Although collected data
were not controlled for confounding factors and the study was not a randomized controlled
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trial, results demonstrated that those children whose mothers had received an iodine
supplement had a more favorable psychometric assessment than control children (47).
Data are beginning to emerge from the largest prospective trial of levothyroxine intervention
in pregnant women. Preliminary results of the CATS study were presented at the
International Thyroid Congress held in Paris in September 2010. The CATS trial was a
prospective randomized study that screened 22 000 women for thyroid status (TSH and FT4
were measured) within the 16th week of gestation. In the intervention group, levothyroxine
was initiated during pregnancy in women with FT4 values lower than the 2.5th percentile
and/or TSH values above the 97.5th percentile. The control group received no intervention.
The offspring of both groups had neuropsychological development testing (Wechsler
Preschool and Primary Scale of Intelligence [WPPSI-III]) performed at 3 years of age. Data
from the study revealed that only 4.5% of women had both an elevated TSH level and a
decreased FT4 level, with the rest of the women with thyroid dysfunction equally divided
into 2 populations with either high TSH or low FT4. The goal of the study was to ascertain
whether the offspring of mothers with abnormal thyroid function had delayed
neuropsychological development and whether this condition was prevented by levothyroxine
treatment. The primary outcome was the mean WPPS-III score and the percentage of
offspring with an IQ lower than 85 points. The primary analysis, which was intention-to-
treat analysis, revealed no significant differences. A secondary analysis, which excluded
women nonadherent to the levothyroxine intervention, revealed a significantly higher
percentage of offspring with IQs lower than 85 in the untreated group. Dr. John Lazarus, the
principle investigator of the CATS trial, stated that these data should be regarded as
preliminary and that further data will be forthcoming. In particular, data were not presented
on whether the 3 treated subgroups (high TSH, low FT4, high TSH and low FT4) showed
any significant difference in offspring IQ. The results of the study may be affected by the
fact that levothyroxine treatment was initiated beyond the critical time point needed for
exogenous thyroid hormone replacement (before the 12th week of gestation [before the fetal
thyroid produces levothyroxine]). Pregnant women were indeed recruited up to the 16th
week of gestation, and the median time of recruitment was 12.6 weeks.
CONCLUSION
Progress has been made in our knowledge of isolated hypothyroxinemia during pregnancy,
but serious gaps remain. The optimal clinical test, which is accurate, inexpensive, and
widely available, does not exist yet. Similarly, trimester-specific reference ranges in iodine-
sufficient and thyroperoxidase antibody–negative populations are yet to be determined. The
problem of iodine deficiency still affects many areas around the world. Iodine deficiency
may have a negative influence on FT4 values and contribute to the incidence and severity of
hypothyroxinemia during pregnancy. However, several studies have evaluated and
confirmed the pivotal role exerted by levothyroxine in the development of the fetal brain.
Furthermore, 2 intervention studies have demonstrated a beneficial effect of iodine
supplementation on neurodevelopment in progeny.
The results of 2 prospective randomized control trials should yield important data on
resolving the impact, or lack thereof, of levothyroxine therapy in women with isolated
hypothyroxinemia during pregnancy. Preliminary data from the CATS study have been
presented at the International Thyroid Congress, and the definitive data analysis should be
forthcoming within the year. The National Institutes of Health Maternal Fetal Medicine Unit
has an ongoing trial that screened 120 000 women during pregnancy. Pregnancy screening
was initiated in the National Institutes of Health trial in 2006, and recruitment has been
completed. Women were divided into 2 groups: 1 group treated with levothyroxine to
normalize TSH or FT4 values and 1 group left untreated. Each group had a cohort of women
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with isolated hypothyroxinemia of pregnancy and a cohort of women with subclinical
hypothyroidism. The primary outcome of the study is intellectual function of children at 5
years of age as measured by the WPPSI-III. The WPPSI-III scores of progeny of treated
women will be compared with the scores of children of untreated women. Secondary
outcomes of the study include assessment of fetal growth, rate of preterm delivery,
preeclampsia, abruption, stillbirth, and development of postpartum thyroid dysfunction.
Results of both studies—complete analysis of the CATS trial and the results of the National
Institutes of Health study (which should be known by 2015)—will have a profound impact
on furthering our understanding of isolated hypothyroxinemia of pregnancy.
At present, difficulties in FT4 testing are still a common problem and trimester-specific
ranges derived from iodine-sufficient areas are lacking. Although studies demonstrating that
levothyroxine therapy in pregnant women with isolated hypothyroxinemia has a positive
impact on the intellectual development of the offspring are intriguing, they are still
inconclusive; thus, levothyroxine treatment of this entity is not recommended. Data suggest
that American women of childbearing age may be receiving inadequate amounts of iodine
during pregnancy. Accordingly, the American Thyroid Association recommends that all
pregnant and breastfeeding women receive daily iodine supplementation, in the form of 150
mcg of potassium iodide. Recent recommendations to decrease the salt intake of all persons
to lower the prevalence of myocardial infarction and stroke is laudatory (48), but may have
the unintended consequence of worsening the degree of iodine deficiency experienced
during pregnancy and lactation (49). It therefore becomes even more critical that
supplemental iodine be included in all prenatal vitamins.
Abbreviations
CATS Controlled Antenatal Thyroid Study
FT3 free triiodothyronine
FT4 free thyroxine
IQ intelligence quotient
LC/MS/MS liquid chromatography/tandem mass spectrometry
PDI Bayley Psychomotor Developmental Index
T3 triiodothyronine
T4 thyroxine
TSH thyrotropin
WPPSI-III Wechsler Preschool and Primary Scale of Intelligence
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Fig. 1.
Panel A, Thyrotropin values during gestation in thyroperoxidase antibody (TPOAb)–
positive and TPOAb-negative euthyroid women. Panel B, Free thyroxine values during
gestation in TPOAb-positive and TPOAb-negative euthyroid women. Adapted with
permission from Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H.
Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease:
Effects on obstetrical complications. J Clin Endocrinol Metab. 2006;91:2587-2591.
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